Manmeet Ahluwalia, MD, MBA, FASCO (@braintumordoc) 's Twitter Profile
Manmeet Ahluwalia, MD, MBA, FASCO

@braintumordoc

Chief Medical Oncology, Dep Director, Chief Scientific Officer, Miami Cancer Institute-interests brain tumors & pt education @baptisthealthSF #tweets are my own

ID: 3426758369

calendar_today16-08-2015 21:28:18

2,2K Tweet

2,2K Followers

1,1K Following

Manmeet Ahluwalia, MD, MBA, FASCO (@braintumordoc) 's Twitter Profile Photo

Exhilarated to see our fellow Vivek Podder, MBBS present research: T-DXd ▶️ significantly longer survival compared to HER2-low pts, with mOS of 9.3 months vs 4.3 months with BM, and 10.7 months vs 6 months without BM. Miami Cancer Institute Research #ASCO24 Baptist Health Reshma Mahtani

Exhilarated to see our fellow <a href="/VPodder/">Vivek Podder, MBBS</a> present research: T-DXd ▶️ significantly longer survival compared to HER2-low pts, with mOS of 9.3 months vs 4.3 months with BM, and 10.7 months vs 6 months without BM. <a href="/MiamiCancerInst/">Miami Cancer Institute Research</a> #ASCO24 <a href="/BaptistHealthSF/">Baptist Health</a> <a href="/DrReshmaMahtani/">Reshma Mahtani</a>
Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

Fantastic presentation by Dr. Shilpa Gupta 👉pts reported outcomes from ph3 EV-302 trial ASCO #ASCO24 👉Rx with enfortumab+pembro significantly improved OS without adversely affecting QOL, pain or functioning. Tom Powles Bladder Cancer Advocacy Network OncoAlert Umang Swami

Fantastic presentation by Dr. <a href="/shilpaonc/">Shilpa Gupta</a> 👉pts reported outcomes from ph3 EV-302 trial <a href="/ASCO/">ASCO</a> #ASCO24 👉Rx with enfortumab+pembro significantly improved OS without adversely affecting QOL, pain or functioning. <a href="/tompowles1/">Tom Powles</a> <a href="/BladderCancerUS/">Bladder Cancer Advocacy Network</a> <a href="/OncoAlert/">OncoAlert</a> <a href="/umangtalking/">Umang Swami</a>
Petros Grivas (@pgrivasmdphd) 's Twitter Profile Photo

Congrats to Shilpa Gupta for stellar presentation on practice changing EV302 trial! Impressive improvement of OS/PFS with NO significant qoL decline! education & careful management of AEs are critical (& future de-escalation trials) Elizabeth Plimack MD ASCO #ASCO24 Uromigos OncoAlert

Manmeet Ahluwalia, MD, MBA, FASCO (@braintumordoc) 's Twitter Profile Photo

Such a privilege to serve as faculty ASCO. It is so satisfying to work with trainees who challenge me every day to think "smarter" and "out of box". It was exhilarating to work with next gen of physicians as we discussed research #ASCO2024. The future of Oncology is bright!

Shilpa Gupta (@shilpaonc) 's Twitter Profile Photo

Had an evening at the ASCO President's reception celebrating the amazing work by @lynn_schuchte Julie Gralow Clifford Hudis Robin Zon, MD, FACP, FASCO to advance ASCO's mission globally. Glad to see old & new friends & the amazing ASCO staff Amanda Narod

Had an evening at the <a href="/ASCO/">ASCO</a> President's reception celebrating the amazing work by @lynn_schuchte <a href="/jrgralow/">Julie Gralow</a> <a href="/CliffordHudis/">Clifford Hudis</a> <a href="/ASCOPres/">Robin Zon, MD, FACP, FASCO</a> 
to advance ASCO's mission globally. Glad to see old &amp; new friends  &amp; the amazing <a href="/ASCO/">ASCO</a> staff <a href="/AmandaBinDC/">Amanda Narod</a>
Nigeria Health Watch (@nighealthwatch) 's Twitter Profile Photo

Today is World Brain Tumour Day 🧠🧠 Did you know that brain cancer constitutes the 13th most common cancer in Nigeria and 19th globally? The incidence of brain tumours in Nigeria is concerning. In 2020, there were 1798 reported cases, according to WHO Nigeria.

Today is World Brain Tumour Day 🧠🧠

Did you know that brain cancer constitutes the 13th most common cancer in Nigeria and 19th globally?

The incidence of brain tumours in Nigeria is concerning. In 2020, there were 1798 reported cases, according to <a href="/WHONigeria/">WHO Nigeria</a>.
Targeted Oncology (@targetedonc) 's Twitter Profile Photo

WATCH: Manmeet Ahluwalia, MD, MBA, FASCO, discusses the takeaways from a study which examined the impact of various therapies, including combination treatments, for patients with metastatic #RCC. #ASCO24 | Manmeet Ahluwalia, MD, MBA, FASCO Baptist Health targetedonc.com/view/improving…

Miami Cancer Institute Research (@miamicancerinst) 's Twitter Profile Photo

The project, “Quantitative Imaging Phenotype Classifier for Distinguishing Radiation Effects from Tumor Recurrence in Glioblastoma,” is spearheaded by Dr. Ahluwalia (Manmeet Ahluwalia, MD, MBA, FASCO) and Pallavi Tiwari, Ph.D., of UW–Madison, who serve as the co-principal investigators of the

The project, “Quantitative Imaging Phenotype Classifier for Distinguishing Radiation Effects from Tumor Recurrence in Glioblastoma,” is spearheaded by Dr. Ahluwalia (<a href="/BrainTumorDoc/">Manmeet Ahluwalia, MD, MBA, FASCO</a>)  and Pallavi Tiwari, Ph.D., of <a href="/UWMadison/">UW–Madison</a>, who serve as the co-principal investigators of the
chadi nabhan MD, MBA, FACP (@chadinabhan) 's Twitter Profile Photo

My second book “THE CANCER JOURNEY” launches 9/24/24 & is available to pre-order a.co/d/f0mwZCZ I leverage storytelling to explain & simplify everything related to cancer from A-Z; written in an easy to read & understand language so it reaches everyone. Check it out.